Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer

Background: Conventional anthracyclines, like epirubicin, are cornerstone drugs for breast cancer treatment of all stages, but their cumulative toxicity could cause life-threatening side effects. Pegylated liposomal doxorubicin (PLD), an effective anti-breast cancer drug, has lower toxicity than con...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenxian, Lv, Kezhen, Teng, Rongyue, Chen, Jida, Xu, Chenpu, Jin, Lidan, Chen, Yongxia, Zhao, Wenhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488192/
https://www.ncbi.nlm.nih.gov/pubmed/34616438
http://dx.doi.org/10.3389/fgene.2021.746114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488192/
https://www.ncbi.nlm.nih.gov/pubmed/34616438
http://dx.doi.org/10.3389/fgene.2021.746114

Ejemplares similares